SCHEMBL4841728

SCHEMBL4841728

C=C(CC(=O)OCc1ccccc1)C(=O)OCC

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
MAPK1 P28482 1/20 0.51
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
MAPT P10636 1/20 0.49
NR1H4 Q96RI1 1/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
PPID Q08752 1/20 0.44
LMNA P02545 2/20 0.44
PKM P14618 1/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1045139 0.91 ALDH1A1 (0.58) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL28209901 0.90 ALDH1A1 (0.46) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL26081601 0.86 PPID (0.47) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL6518733 0.86 ALDH1A1 (0.46) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL9355135 0.85 ALDH1A1 (0.50) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL6521008 0.85 ALDH1A1 (0.50) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL6519457 0.85 ALDH1A1 (0.49) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL6523916 0.85 ALDH1A1 (0.51) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL698394 0.84 ALDH1A1 (0.51) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL1557559 0.84 ALDH1A1 (0.61) ALDH1A1L3MBTL1MAPK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0242618-B1 Transparent optical article and process for preparing same NIPPON OILS & FATS CO LTD (JP) 1994-11-02 EP claimed
EP-0242618-A2 Transparent optical article and process for preparing same NIPPON OIL AND FATS COMPANY, LIMITED (JP) 1987-10-28 EP claimed
US-7452875-B2 Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2008-11-18 US disclosed
US-7427611-B2 Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2008-09-23 US disclosed
US-7410962-B2 Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2008-08-12 US disclosed
US-20080085889-A1 Amidomethyl-Substituted 1-(Carboxyalkyl) Cyclopentyl-Carbonylamino-Benzazepine-N-Acetic Acid Compounds, Process and Intermediate Products for Their Preparation and Pharmaceutical Compositions Containing Them SOLVAY PHARMACEUTICALS GMBH (DE) 2008-04-10 US disclosed
US-20070265244-A1 AMIDOMETHYL-SUBSTITUTED 1-(CARBOXYALKYL) CYCLOPENTYL-CARBONYLAMINO-BENZAZEPINE-N-ACETIC ACID COMPOUNDS, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SOLVAY PHARMACEUTICALS GMBH (DE) 2007-11-15 US disclosed
US-7262184-B2 Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2007-08-28 US disclosed
US-20060281732-A1 Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them SOLVAL PHARMACEUTICALS GMBH (DE) 2006-12-14 US disclosed
EP-1670814-A1 AMIDOMETHYL SUBSTITUTED 1-(CARBOXYALKYL)-CYCLOPENTYLCARBONYLAMINO-BENZAZEPINE-N-ACETIC ACID DERIVATIVES, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS Solvay Pharmaceuticals GmbH (DE) 2006-06-21 EP disclosed
US-20050119247-A1 Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2005-06-02 US disclosed
WO-2005030795-A1 AMIDOMETHYL SUBSTITUTED 1-(CARBOXYALKYL)-CYCLOPENTYLCARBONYLAMINO-BENZAZEPINE-N-ACETIC ACID DERIVATIVES, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS SOLVAY PHARMACEUTICALS GMBH (DE) 2005-04-07 WO disclosed
EP-0242618-B1 Transparent optical article and process for preparing same NIPPON OILS & FATS CO LTD (JP) 1994-11-02 EP disclosed
US-4948854-A COPOLYMER INCLUDING ITACONIC ACID DIESTER SEIKO EPSON CORPORATION (JP) 1990-08-14 US disclosed
EP-0242618-A2 Transparent optical article and process for preparing same NIPPON OIL AND FATS COMPANY, LIMITED (JP) 1987-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281732-A1 Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them ECE1, MME, ANPEP ALDH1A1 368/4885L3MBTL1 1996/4885MAPK1 2746/4885
US-20070265244-A1 AMIDOMETHYL-SUBSTITUTED 1-(CARBOXYALKYL) CYCLOPENTYL-CARBONYLAMINO-BENZAZEPINE-N-ACETIC ACID COMPOUNDS, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ECE1, MME, ANPEP ALDH1A1 394/4885L3MBTL1 2039/4885MAPK1 2672/4885
US-20050119247-A1 Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them ECE1, MME, ANPEP ALDH1A1 333/4885L3MBTL1 1978/4885MAPK1 2330/4885
US-20080085889-A1 Amidomethyl-Substituted 1-(Carboxyalkyl) Cyclopentyl-Carbonylamino-Benzazepine-N-Acetic Acid Compounds, Process and Intermediate Products for Their Preparation and Pharmaceutical Compositions Containing Them ECE1, MME, ANPEP ALDH1A1 394/4885L3MBTL1 2039/4885MAPK1 2672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.